First-line immunotherapy for metastatic kidney cancer
The following is a Practice Update interview with Dr Eric [...]
Combination immunotherapy: the new standard of care for metastatic kidney cancer
The following video interviews discuss combinations of immunotherapy drugs and [...]
A new class of anti-cancer drug for kidney cancer shows promise
Researchers in America are looking at a new class of [...]
Joint working project between the Royal Marsden and Novartis to improve cancer services
A new joint working project between Novartis and the Royal [...]
Gut bacteria ‘boost’ cancer immunotherapy
Researchers from France and the USA have shown that the [...]
Researchers discover the mechanism that causes kidney cancer to recur
New research published in the journal Nature Communications this month has identified [...]
Implications of the complex genomic landscape of RCC for targeted therapy and immunotherapy
This article discusses the multiple gene changes (genetic heterogeneity) found [...]
Initiation of phase 2 clinical trial of glutaminase inhibitor plus everolimus for renal cell carcinoma
Calithera Biosciences, an American pharmaceutical company focused on developing drugs [...]
MicroRNA as a potential biomarker for kidney cancer
Recently, researchers are focusing on microRNAs (miRNAs) circulating in the [...]
Recommendations for the management of rare kidney cancers
Patients diagnosed with a rare kidney cancer are often treated [...]
